UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Apathy and Depression in Huntington’s Disease: Distinct Longitudinal Trajectories and Clinical Correlates

The journal of neuropsychiatry and clinical neurosciences, 2023-01, Vol.35 (1), p.69-76

2023

Volltextzugriff (PDF)

Agmatine mitigates behavioral abnormalities and neurochemical dysregulation associated with 3-Nitropropionic acid-induced Huntington's disease in rats

Neurotoxicology (Park Forest South), 2024-05, Vol.102, p.12-28

2024

Volltextzugriff (PDF)

Secukinumab treatment for ankylosing spondylitis and concomitant Huntington's disease: real-world experience

Clinical and experimental rheumatology, 2024-03, Vol.42 (3), p.767

2024

Volltextzugriff (PDF)

Combination therapy with Coenzyme Q₁₀ and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases

Journal of neurochemistry, 2009-06, Vol.109 (5), p.1427-1439

2009

Volltextzugriff (PDF)

Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington’s disease

Molecular therapy, 2023-01, Vol.31 (1), p.282-299

2023

Volltextzugriff (PDF)

TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31

Human molecular genetics, 2018-08, Vol.27 (16), p.2893-2912

2018

Volltextzugriff (PDF)

Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin―proteasomal and autophagy systems

Human molecular genetics, 2012-12, Vol.21 (24), p.5280-5293

2012

Volltextzugriff (PDF)

Apoptosis and Caspases in Neurodegenerative Diseases

The New England journal of medicine, 2003-04, Vol.348 (14), p.1365-1375

Friedlander, Robert M

2003

Volltextzugriff (PDF)

Allosteric activation of M₄ muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice

Proceedings of the National Academy of Sciences - PNAS, 2015-11, Vol.112 (45), p.14078-14083

2015

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study

CNS spectrums, 2021-04, Vol.26 (2), p.164-165

2021

Volltextzugriff (PDF)

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG

Neurology, 2006-01, Vol.66 (2), p.250

2006

Volltextzugriff (PDF)

Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease

The Journal of neuroscience, 2002-03, Vol.22 (5), p.1592-1599

2002

Volltextzugriff (PDF)

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

Human molecular genetics, 2018-07, Vol.27 (14), p.2490-2501

2018

Volltextzugriff (PDF)

Chorea

Continuum (Minneapolis, Minn.), 2019-08, Vol.25 (4), p.1001-1035

Termsarasab, Pichet

2019

Volltextzugriff (PDF)

Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data

Expert opinion on pharmacotherapy, 2019-12, Vol.20 (18), p.2209-2221

2019

Volltextzugriff (PDF)

Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies

Handbook of experimental pharmacology, 2011 (200), p.267

2011

Volltextzugriff (PDF)

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

BMJ open, 2022-06, Vol.12 (6), p.e062740-e062740

2022

Volltextzugriff (PDF)

The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ

EBioMedicine, 2024-05, Vol.103, p.105124, Article 105124

2024

Volltextzugriff (PDF)

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects

Movement disorders, 2010-09, Vol.25 (12), p.1924-1928

2010

Volltextzugriff (PDF)

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases

Translational psychiatry, 2013-12, Vol.3 (12), p.e332-e332

2013

Volltextzugriff (PDF)

Adenosine A 1 receptor agonist, N6-cyclohexyladenosine, attenuates Huntington's disease via stimulation of TrKB/PI3K/Akt/CREB/BDNF pathway in 3-nitropropionic acid rat model

Chemico-biological interactions, 2023-01, Vol.369, p.110288

2023

Volltextzugriff (PDF)

A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice

Human molecular genetics, 2016-11, Vol.25 (22), p.4920-4938

2016

Volltextzugriff (PDF)

Cause or compensation?-Altered neuronal Ca 2+ handling in Huntington's disease

CNS neuroscience & therapeutics, 2018-04, Vol.24 (4), p.301-310

2018

Volltextzugriff (PDF)

Tauroursodeoxycholic Acid, A Bile Acid, is Neuroprotective in a Transgenic Animal Model of Huntington's Disease

Proceedings of the National Academy of Sciences - PNAS, 2002-08, Vol.99 (16), p.10671-10676

2002

Volltextzugriff (PDF)

Immunomodulation – a disease‐modifying avenue for treatment of Huntington's disease?

Journal of neurochemistry, 2016-06, Vol.137 (5), p.670-672

Bjorkqvist, Maria

2016

Volltextzugriff (PDF)

1 – 25 von 381

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

SprachePortugiesisch

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(148)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(286)
Huntington Disease - Drug Therapy
(228)
Male
(105)
Animals
(103)
Female
(91)
Adult
(77)
Middle Aged
(76)
Huntington's Disease
(66)
Huntington Disease - Metabolism
(57)
Huntingtons Disease
(55)
Drug Therapy
(52)
Aged
(43)
Disease Models, Animal
(43)
Huntington Disease - Physiopathology
(43)
Alzheimer's Disease
(39)
Huntington Disease - Genetics
(38)
Mice
(38)
Parkinson Disease - Drug Therapy
(38)
Parkinson's Disease
(28)
Clinical Trials As Topic
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Apathy and Depression in Huntington’s Disease: Distinct Longitudinal Trajectories and Clinical Correlates

Agmatine mitigates behavioral abnormalities and neurochemical dysregulation associated with 3-Nitropropionic acid-induced Huntington's disease in rats

Secukinumab treatment for ankylosing spondylitis and concomitant Huntington's disease: real-world experience

Combination therapy with Coenzyme Q₁₀ and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases

Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington’s disease

TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31

Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin―proteasomal and autophagy systems

Apoptosis and Caspases in Neurodegenerative Diseases

Allosteric activation of M₄ muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice

Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG

Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

Chorea

Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data

Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases

Adenosine A 1 receptor agonist, N6-cyclohexyladenosine, attenuates Huntington's disease via stimulation of TrKB/PI3K/Akt/CREB/BDNF pathway in 3-nitropropionic acid rat model

A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice

Cause or compensation?-Altered neuronal Ca 2+ handling in Huntington's disease

Tauroursodeoxycholic Acid, A Bile Acid, is Neuroprotective in a Transgenic Animal Model of Huntington's Disease

Immunomodulation – a disease‐modifying avenue for treatment of Huntington's disease?

Aktive Filter

Suchergebnisse filtern